
1. infect immun. 2013 jun;81(6):1984-9. doi: 10.1128/iai.00016-13. epub 2013 mar 18.

anti-pfs25 human plasma reduces transmission plasmodium falciparum isolates
that diverse genetic backgrounds.

da df(1), dixit s, sattabonkot j, mu j, abate l, ramineni b, ouedraogo jb,
macdonald nj, fay mp, su xz, cohuet a, wu y.

author information: 
(1)institut de recherche en sciences de la sant√© (irss), bobo-dioulasso, burkina 
faso.

pfs25 leading candidate malaria transmission-blocking vaccine whose
potential demonstrated phase 1 trial recombinant pfs25
formulated montanide isa51. limited sequence polymorphism, the
anti-pfs25 antibodies induced vaccine likely have
transmission-blocking -reducing activity most, all, field
isolates. test hypothesis, evaluated transmission-blocking activities 
by membrane feeding assay anti-pfs25 plasma pfs25/isa51 phase 1 trial
against plasmodium falciparum parasites patients two different
geographical regions world, thailand burkina faso. parallel,
parasite isolates patients sequenced pfs25 gene and
genotyped seven microsatellites. results indicate despite different 
genetic backgrounds among parasite isolates, pfs25 sequences highly
conserved, single nonsynonymous nucleotide polymorphism detected 1 of
41 patients thailand burkina faso. anti-pfs25 immune plasma had
significantly higher transmission-reducing activity parasite isolates
from two geographical regions nonimmune controls (p < 0.0001).

doi: 10.1128/iai.00016-13 
pmcid: pmc3676035
pmid: 23509152  [indexed medline]

